Skip to Content

First-line treatment of claudin 18.2-positive metastatic pancreatic cancer with zolbetuximab, gemcitabine, and nab-paclitaxel

Dr. Wungki Park presents an intriguing study of zolbetuximab in this MEDtalk. This innovative monoclonal antibody, which is the first of its kind, targets CLDN 18.2 and induces ADCC/CDC in patients with metastatic pancreatic cancer.

Wungki Park

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top